Lymph node dissection in cutaneous melanoma: surgical and oncological implications

Area of Science:

• Oncology
• Surgical Pathology
• Nuclear Medicine

Background:

• Elective lymph node dissection (ELND) for primary melanoma yielded disappointing results.
• Sentinel Lymph Node Dissection (SLND) emerged to identify the first draining lymph node, avoiding unnecessary ELND for negative nodes.
• SLND is a crucial diagnostic tool in primary melanoma management.

Purpose of the Study:

• To evaluate the diagnostic and prognostic value of Sentinel Lymph Node Dissection (SLND) in primary melanoma.
• To discuss the multidisciplinary approach and current standards for SLND in melanoma.
• To highlight the limitations and future directions for SLND in melanoma treatment.

Main Methods:

• Triple approach for SLN detection: Technetium and patent blue injection, followed by gamma probe tracing.
• Histopathological examination of alternating series sections of the entire lymph node.
• Comparison with molecular biologic procedures like tyrosinase RT-PCR, noting their limitations.

Main Results:

• Histopathology of the whole lymph node is considered the optimal analytical method.
• Molecular biologic techniques like tyrosinase RT-PCR are time-consuming and yield contradictory results.
• SLND is an interdisciplinary approach involving surgery, dermatology, pathology, and nuclear medicine.

Conclusions:

• The diagnostic and prognostic value of SLND for cutaneous melanoma needs further confirmation through ongoing prospective clinical trials.
• SLND is currently a diagnostic procedure, not a therapeutic one.
• Informed consent and risk-benefit assessment are critical when considering SLND for melanoma patients.